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ABSTRACT 
 
Background 
Dysphagia after stroke is common, especially in severely affected, tracheotomised patients. 
In a pilot trial, pharyngeal electrical stimulation (PES) improved swallowing function in this 
group of patients. The PHAryngeal electrical STimulation for early decannulation in 
TRACheotomised stroke patients with neurogenic dysphagia trial (PHAST-TRAC) was 
designed to replicate and extend this single-centre experience. 
Methods 
Patients with recent stroke who required tracheotomy were randomised to receive three days 
of PES or sham. All patients had the stimulation catheter inserted; sham treatment was 
applied by connecting the base station to a simulator box instead of the catheter. 
Randomisation was done via a computerised interactive system with randomisation (stratified 
by site) in blocks of 4 patients per site. Patients and investigators applying PES were not 
masked. The primary-endpoint was assessed blinded to treatment assignment by a separate 
investigator at each site. The primary outcome was readiness for decannulation 24-72 hours 
post-treatment, assessed using fiberoptic endoscopic evaluation of swallowing and based on 
a standardised protocol including absence of massive saliva, presence of spontaneous 
swallows and laryngeal sensation. We planned a sequential statistical analysis of superiority 
for the primary endpoint. Interim analyses were to be performed after primary outcome data 
were available for 50 patients (futility), 70 patients, and every additional 10 patients thereafter 
up to 140. Analysis was by intention-to-treat. The trial was registered as ISRCTN18137204. 
Findings 
From 29th May 2015 to 5th July 2017, 69 patients (PES 35, sham 34) from 9 sites (7 acute 
care hospitals, 2 rehabilitation facilities) in Germany, Austria and Italy were included: PES 
group mean age 61.7 (SD 13.0) years, 8 (23%) patients with haemorrhagic stroke, median 
time onset to randomisation 28.0 [IQR 20, 49] days; sham group age 66.8 (10.3) years, 12 
(35%) patients with haemorrhagic stroke, onset to randomisation 28.0 [18, 40] days). The 
Independent Data & Safety Monitoring Board recommended to stop the trial early for efficacy 
after 70 patients had been recruited and primary endpoint data of 69 patients were available. 
This decision was approved by the steering committee. PES was associated with more 
patients being ready for decannulation as compared to sham: 17 (49%) vs. 3 (9%), odds ratio 
(OR) 7.00 (2.41-19.88), p=0.00082). No patient required recannulation within 48 hours or 
during their documented follow-up period up to 30 days or hospital discharge. Adverse 
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events (AEs) were reported in 24 patients (69%) of the PES group and 24 patients (71%) of 
the sham group. The number of patients with at least one serious adverse event (SAE) did 
not differ between the groups: 10 (29%) vs. 8 (23%), OR 1.3 (0.44-3.83), p=0.7851). 7 
patients (20%) from the PES group and 3 patients (9%) from the sham group died during the 
study period. None of the patient deaths or SAEs reported were judged to be PES-treatment- 
or investigational device-related. 
Interpretation 
PES increased the proportion of patients with stroke and subsequent tracheotomy who were 
ready for decannulation in this study population, many of whom received PES within a month 
of their stroke. Future trials should confirm whether PES is beneficial in tracheostomised 
patients who receive stimulation similarly early after stroke and explore its effects in other 
cohorts. 
Funding 
Phagenesis Ltd., Manchester, UK 
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RESEARCH IN CONTEXT 
Evidence before this study 
We searched PubMed for manuscripts pubished in English from inception until the 16th May 
2018 with the terms “stroke” and “dysphagia” in combination with “treatment”, “stimulation”, 
“therapy”, “rehabilitation”, “tracheotomy”, “tracheostomy” or “decannulation”. Reference lists 
from identified reviews and trial publications were also checked for additional trials. We 
identified 4 randomised-controlled trials (RCT) and one meta-analysis where pharyngeal 
electrical stimulation (PES) was delivered in non-ventilated stroke patients with 
heterogeneous results. However, there was one single-centre pilot RCT recruiting specifically 
tracheotomised stroke patients, which had previously been conducted by the leading study 
site of the PHAST-TRAC trial. These patients could not be decannulated after successful 
weaning from the respirator because of severe and persistent post stroke dysphagia (PSD). 
PES was significantly associated with improvement of airway protection and remission of 
dysphagia. 
Overall, PSD remains one of the most debilitating complications for stroke victims in both the 
hospital and community healthcare settings conferring a significant comorbidity with a 6-
times increased risk of aspiration pneumonia and a 3-times increased mortality. This is 
brought all the more into focus as there remains little or no hope of life changing treatments 
for these patients and specifically the Cochrane Database for Therapies in Dysphagia after 
Stroke, reported little evidence for any treatments being effective in this disorder. 
 
Added value of this study 
In the present study, PHAryngeal electrical STimulation for early decannulation in 
TRACheotomised stroke patients with neurogenic dysphagia (PHAST-TRAC), a multicentre 
randomised sham-controlled trial of severely dysphagic, tracheotomised stroke patients, PES 
allowed investigators to designate 17 of 35 (49%) patients as ready for decannulation in 
comparison with 3 of 34 (9%) in the control group (primary endpoint). A prespecified 
subgroup-analysis revealed that response to PES-treatment related to a shorter time from 
stroke onset to randomisation, and shorter period on mechanical ventilation. With regards to 
secondary outcomes, following both the randomised and open-label phases of the study, 37 
of 65 (57%) patients who received PES were ready for decannulation. Patients responding to 
PES (ready for decannulation) were discharged from hospital significantly earlier than non-
responders (not ready for decannulation). In 4 of 15 (27%) patients, not responding to a 
treatment cycle of PES (10 minutes per day for three consecutive days), a second treatment 
cycle proved to be effective. A summary post-hoc meta-analysis of results from PHAST-
TRAC and the previous pilot-trial in the same population and with the same outcome 
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measure showed that treatment effects were similar and that PES was associated with a 
>10-times chance of decannulation as compared to sham. 
 
Implications of all the available evidence 
This study provides evidence that PES is effective in promoting earlier decannulation in 
tracheotomised stroke patients with PSD. The size of the difference between active and 
control groups could constitute a significant change to current approaches in the ability for 
clinicians to treat these patients, where at present there is no recognised treatment option 
available. However, due to the small sample size and differences in treatment effects in 
subgroups, further trials are needed to corroborate these encouraging findings. 
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INTRODUCTION 
Post-stroke dysphagia (PSD) is a common complication of acute stroke affecting up to 80% 
of patients, and 11-50% even at 6 months.1-3 PSD interferes with oral feeding and is 
associated with dehydration, malnutrition, aspiration pneumonia, prolonged hospital stay, 
poor long-term outcome and increased mortality.4-6 Around 1-2% of all stroke patients, and 
25% of stroke patients treated on the intensive care unit (ICU), require a tracheotomy7-10 due 
to severe dysphagia with prolonged insufficient airway protection, or the need for long-term 
ventilation.11,12 Despite the clinical benefits provided by tracheotomy during the acute stage 
of the illness,12 the continuing presence of the cannula once the patient has been 
successfully weaned from the respirator has negative consequences for timely rehabilitation, 
patient comfort, days of hospitalisation10, hospital re-admission-rates,13 and the financial 
costs of care.13,14 Further, the presence of a tracheotomy tube at discharge from the ICU is 
predictive of poorer outcome, in part because of cannula-related complications.15,16 In stroke 
patients, severe dysphagia with related insufficient airway protection is often the main reason 
why decannulation cannot be performed even three months post stroke.12,17 
Currently, treatment options for accelerating decannulation are very limited.1 Pharyngeal 
electrical stimulation (PES) is a novel technique shown to enhance reorganisation of the 
swallow-related motor-cortex, facilitate activation of cortico-bulbar pathways, and increases 
salivary substance P levels, a swallow-related neurotransmitter.18-20 Studies using PES to 
treat PSD in unselected stroke patients showed heterogeneous results.21-23 However, in a 
single-centre, randomised controlled pilot study recruiting 30 tracheotomised acute stroke 
patients, dysphagia improved enabling decannulation in 15/20 (75%) patients of the 
treatment group, whereas only 2/10 (20%) of control patients showed spontaneous remission 
of PSD sufficient enough to allow for subsequent removal of the tracheal cannula.24 The 
PHAryngeal electrical STimulation for early decannulation in TRACheotomised stroke 
patients with neurogenic dysphagia trial (PHAST-TRAC) was designed to replicate, validate, 
and extend this single-centre experience to a larger phase III design.25 
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METHODS 
Study Design and Participants 
PHAST-TRAC was an international, prospective, randomised-controlled, single-blind trial 
with sequential design and analysis using a triangular test.26 The study included a second 
part where non-responding patients in either randomised group were given open-label 
treatment. The study protocol was approved by all relevant national competent authorities 
(Bundesinstitut für Arzneimittel und Medizinprodukte of Germany, Agentur für Gesundheit 
und Ernährungssicherheit GmbH of Austria, Ministero della Salute of Italy) and local ethics 
committees for the participating sites, and all patients or their legal representative provided 
written informed consent. Patients were enrolled across 9 centres (7 acute care hospitals, 2 
rehabilitation facilities) in Germany, Austria and Italy. Details on the study protocol have been 
published previously.25 The study was sponsored by Phagenesis Ltd., Manchester, UK. A 
steering committee was responsible for the design, conduct, and reporting of the study. 
Interim-analyses were reviewed by an Independent Data and Safety Monitoring Board 
(IDSMB) after randomisation of 50 and 70 patients, respectively. Pre-specified stopping rules 
are given below (statistical analysis). The trial was registered as ISRCTN18137204 
(http://www.isrctn.com). The study protocol and the statistical analysis plan is available at: 
http://www.phagenesis.com/wp-content/uploads/2018/04/PHAST-
TRAC_Studyprotocol_AnalysisPlan.pdf. The authors will share a subset of anonymised 
individual patient data with the international VISTA Rehabilitation Collaboration 
(http://www.vista.gla.ac.uk). 
 
Patient Population 
Patients were eligible for study participation if they were over 18 years of age, had presented 
with a supratentorial stroke (haemorrhagic or ischemic), were mechanically ventilated for at 
least 48 hours post-stroke, were successfully weaned from mechanical ventilation but 
remained tracheotomised, had been free of sedation for at least 3 days at the time of first 
decannulation screening, scored ≥-1 points on the Richmond Agitation and Sedation Scale 
(RASS),27 and could not be decannulated due to severe dysphagia. After signing the 
informed consent form, patients’ readiness for decannulation was assessed twice over 24-72 
hours and a minimum 10 days after the stroke using fiberoptic endoscopic evaluation of 
swallowing (FEES). The presence of massive pooling of saliva, limited spontaneous 
swallows (<1/minute), and/or no sensation elicited by endoscope contact with the laryngeal 
vestibule (for details of the algorithm see Figure S1 in the Supplementary Appendix) meant 
that patients were not ready for decannulation.28 Key exclusion criteria were infratentorial 
stroke, pre-existing dysphagia, pre-existing disease that typically causes dysphagia (for 
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example Parkinson’s disease, motor neuron disorders), participation in any other study 
potentially influencing the outcome of PES, presence of a cardiac pacemaker or an 
implantable defibrillator, nasal deformity or previous oesophageal surgery or any other 
circumstance where placement of a standard nasogastric tube would be deemed unsafe, 
need for high levels of oxygen supply (>2 l/min), required emergency treatment, or had less 
than three months life expectancy (for a complete list of in- and exclusion criteria see Table 
S1 in the Supplementary Appendix). 
 
Randomisation and masking 
Patients were randomised to PES or sham 1:1 via a computerised interactive wireless 
randomisation system (IWRS) that applied randomisation stratified by study site in blocks of 
4 patients per centre.  At each trial site, the randomisation procedure was obtained from the 
IWRS by a dedicated group of investigators responsible only for treatment application. All 
other investigators and healthcare workers not involved in treatment were blinded. 
Conversely, treating investigators were not involved in any outcome assessment or any other 
study-related activities such as patient recruitment or dysphagia assessment prior to or after 
randomisation. As with many device studies, blinding patients could not be guaranteed 
because they could, in principle, feel whether PES was applied or not. In all other aspects, 
PES and sham condition were kept as similar as possible. PES or sham stimulation had to 
be commenced within 24 hours of randomisation. 
 
Procedures 
For the study intervention (PES), a commercial device (Phagenyx®, Phagenesis Ltd, 
Manchester UK), which comprises a nasogastric feeding catheter housing stimulation ring-
electrodes, and a computerised base station that delivers stimulation in the range 1-50 mA at 
5Hz was used. In all patients the stimulation catheter was placed prior to randomisation. The 
catheter was inserted via the nose to an aboral depth related to the patient’s height so that 
the pair of treatment ring electrodes located on the outer surface of the catheter were 
adjacent to the pharynx. A coloured zone on the outer catheter surface and visible at the 
nares also aided correct placement and easy confirmation of correct electrode depth. 
Duration of catheter insertion procedure (minutes), ease of catheter insertion (rated on a 
scale of 1-very difficult to 7-very easy), and electrode depth from nostrils (cm) were captured. 
In all patients, (active) PES or sham stimulation was given on three consecutive days for 10 
minutes. The current intensity (mA) at which PES-treatment was delivered was individually 
adjusted and optimised at every session by the healthcare worker interacting the with the 
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base station’s touchscreen in response to patient responses. This treatment optimisation 
procedure involved increasing the current intensity incrementally from 1 mA to detect the 
perceptual threshold (PT – patient first aware of stimulation) and then maximum tolerated 
threshold (MTT – patient no longer wants current increased further) intensity levels three 
times each respectively. Thereafter, the optimal treatment intensity was automatically 
calculated by the base station using the average values of three trials according to the 
formula PT + 0.75 x (MTT - PT).21 
In the sham group, the optimisation procedure was imitated as closely as possible to mitigate 
any bias or effect of time spent interacting with the patient during (real) PES but no current 
was applied. To this end, in sham patients, the base station was connected to a small patient 
simulator box instead of the stimulation catheter placed in the patient. The patient simulator 
box allowed the treating investigator to interact with the base station as if the stimulation 
catheter were connected and a real stimulation was about to be delivered. Moreover, in both 
treatment groups (PES and sham), the connecting ends of the stimulation catheter, base 
station and patient simulator were hidden inside a disposable “blinding pouch” to further 
reduce the risk of bias or unblinding (Figure S2 in the Supplementary Appendix illustrates the 
setup for the PES and sham treatments). Following the treatment optimisation procedure, the 
treating investigator then delivered 10 minutes of PES or sham stimulation. 
Following randomised treatment, the primary outcome was assessed at 24-72 hours after the 
last stimulation. All patients who had not responded (i.e. showing persistent dysphagia 
requiring the tracheal cannula to be left in situ with the tracheal cuff inflated), irrespective of 
treatment assignment, were offered open-label treatment with PES. 24-72 hours after the last 
open-label PES-treatment, outcome was again assessed using the same FEES-based 
decannulation algorithm. 
 
Outcomes 
The primary endpoint of the study was readiness for decannulation after 3 days of PES-
treatment, assessed as described above using the FEES-based algorithm.28 Readiness for 
decannulation could be clinically followed by either immediate removal of the tracheal tube or 
cuff deflation (planned analysis). The primary-endpoint assessment was performed blinded 
to treatment assignment by a separate investigator at each site. Investigators from all sites 
being responsible for outcome assessment were trained in using this algorithm. In addition, 
to ensure that the decannulation procedure was correctly applied at the study sites, all 
FEES-videos of the primary endpoint assessment were anonymised and adjudicated by an 
independent FEES-Review-Board (SMG, TW, PZ) not involved in any other study-related 
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activity. Results of the board’s rating were used in post-hoc analyses and not communicated 
with the sites during the conduct of the trial.  
Secondary endpoints were treatment effect in delayed and retreated patients, necessity of 
recannulations (at day 2 and during follow-up of 30 days or until discharge, whichever is 
first), PES treatment parameters, dysphagia scores (dysphagia severity rating scale (DSRS); 
functional oral intake scale (FOIS), Table S2 and S3 in the Supplementary Appendix),  
severity of stroke (modified Rankin Scale and National Institutes of Health Stroke Scale 
scores) (at day 2, during follow-up of 30 days or until discharge, whichever was first), length 
of stay on different levels of care, Speech and Language Therapy (SLT) management plan, 
number and type of adverse events (AEs), including adverse device events (ADEs).22,29  
For post-hoc analysis, the binary FEES-score (primary endpoint ratings from the local 
investigators and independent FEES review board) was transformed in to an ordered 
categorical outcome ranging from 0 (none of the three items present) to 3 (all three items 
present).  
 
Statistical analysis 
Group sequential monitoring of cumulative data was performed using a triangular test.26 The 
maximum number of patients, where the upper and lower decision boundaries met, was set 
at 140 with the aim of being able to detect an absolute difference between the groups of 25% 
assuming that the control rate would be 20%, overall type I error of 0.05, and power 0.80 (the 
90th percentile of the required sample size was estimated to be 126 patients). Interim 
analyses were to be performed after primary outcome data were available for 50 (futility) and 
then at 70 and for every additional 10 patients thereafter up to 140. Decision rules allowed.25  
1. Stopping the trial for futility, i.e. where the difference between treatment 
groups was very unlikely to equal or exceed 25%, at 50 patients; 
2. Stopping the trial for superiority of PES treatment, i.e. readiness for 
decannulation is more common with PES and equals or exceeds an absolute 
difference between groups of 25%, at 70, 80, 90, 100, 110, 120, 130 and 140 
patients. 
Patients who did not reach a primary outcome were considered not ready for decannulation. 
For sensitivity purposes, the heterogeneity of the treatment effect on the primary outcome 
was assessed in pre-specified subgroups (age, sex, stroke type, time from onset to 
randomisation, duration of mechanical ventilation, baseline stroke severity, and stimulation 
intensity) by adding an interaction term and using exact inference for logistic regression 
(LogXact11,Cytel Inc., Cambridge, USA).30 
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Other outcomes were analysed using Fisher’s exact test for binary data, Mann-Whitney-U 
test for ordinal data, and Student’s t test (pooled) for continuous data. Regressions were 
performed using binary logistic regression, Cox regression and multiple linear regression. 
Kaplan-Meier analysis was used on length of stay data. Data are shown as number (%), 
median (interquartile range, IQR), mean (standard deviation, SD) and either mean difference 
(MD), hazard ratio (HR), odds ratio (OR) with 95%-confidence-intervals (CI). The nominal 
level of significance for all analyses, including interaction testing, was p<0.05. No adjustment 
was made for multiplicity of testing for secondary analyses, and all analyses were by 
intention to treat. Statistical analyses were performed by the University of Utrecht (RS and 
IvdT) (sequential analysis of the primary endpoint using PEST 4.4)31 and Cytel Inc. (all other 
analyses using R-project software, version R-3.4.1).32 
 
Role of the funding source 
The study was sponsored and funded by Phagenesis Ltd. (Manchester, UK). A scientific 
design committee (RD, IvdT, SM, SH and PB) was responsible for the design of the study. A 
steering committee (PMB (chair) and RD) was responsible for the conduct and reporting of 
the study and interpretation of the results. The study was managed by a Clinical Research 
Organisation (FAKKEL, Belgium, for further details see Supplementary Appendix) that also 
verified the accuracy of all collected data. The sponsor was involved in the design of the 
study; compensated sites for data collection, the Clinical Research Organisation (FAKKEL) 
for study management and source data verification, University Medical Centre Utrecht (The 
Netherlands) and Cytel Inc. (Cambridge, USA) for data analysis and contributed to the data 
interpretation and the writing of the manuscript. Interim-analyses were reviewed by an 
Independent Data and Safety Monitoring Board (IDSMB) without involvement of the sponsor 
or the steering committee after 50 and 70 patients had been recruited. The steering 
committee and all other authors had full access to all data. The corresponding author had 
final responsibility for the decision to submit for publication. 
 
RESULTS 
The study was conducted between 29th May 2015 and 5th July 2017. Figure 1 shows the 
CONSORT diagram with the flow of patients through the randomised and open-label parts of 
the study. The stimulation catheter could not be placed in one patient and therefore 69 of the 
70 successfully screened patients underwent randomisation. A total of 35 patients were 
assigned to receive early PES and 34 to receive sham stimulation during the blinded study 
phase. Sequential analysis after 50 patients demonstrated no futility. After 70 patients had 
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been recruited, sequential analysis indicated superiority in favour of PES treatment (Figure 
S3 in the Supplementary Appendix) such that the IDSMB recommended that the trial should 
stop. The one patient in whom the stimulation catheter could not be placed and who was not 
randomised was initially adjudicated as a treatment failure and only later when this mistake 
was detected, was removed from the intention to treat population. The steering committee 
reviewed the same data and IDSMB advice to stop and agreed with the decision (see table 
S4 in the Supplementary Appendix). 
25 (36%) patients were women and the mean age was 64 (SD 12) years. 49 (71%) patients 
had an ischemic stroke, and 20 (29%) an intracerebral haemorrhage. The mean NIHSS was 
17.5 (SD 4.6), and patients were randomised at a median of 28 [IQR 19, 41] days after ictus 
and following 15 [IQR 9, 22] days of mechanical ventilation (Table 1). 
17 of 35 patients (49%) in the PES group and 3 of 34 patients (9%) in the sham group were 
judged to be ready for decannulation after the blinded first part of the study (OR 7.00, 95% CI 
2.41-19.88, p=0.00082; Table 2). In predefined subgroups, significant treatment-by-subgroup 
interactions were present, these favouring treatment in patients treated earlier after stroke, or 
with a shorter duration of mechanical ventilation (Figure 2). Following the decision to 
decannulate, 14 of 17 patients in the PES group were decannulated and the cuff was 
permanently deflated in 3 (Table 2). No patients who had decannulation performed required 
re-cannulation over the next 48 hours, or during their documented follow-up period up to 
hospital discharge. The decannulation assessment occurred mainly 24-48 hrs after the third 
day of treatment/sham (N=21 in sham, 24 in treatment arm); the remaining were assessed in 
the time window 48-72 hrs (N=13 in sham,10 in treatment arm). 
15 of the 35 patients (43%) from the early treatment group received a second (retreat) cycle 
of PES during the unblinded study phase, with one patient (3%) withdrawing; subsequently, 
four of the 15 retreated patients (27%) were judged to be ready for decannulation. 30 
patients from the sham group received a first (delayed) cycle of PES during the unblinded 
second part of the study; with a further one (3%) withdrawn due to identification of a bleeding 
gastric ulcer precluding catheter insertion. 16 (53%) of these patients were judged to be 
ready for decannulation after three days of PES (Table 2, subheading “open label (Part 2) of 
the study”). Taking account of both the randomised and open-label components of the study, 
and following at least one course of PES, a total of 57% (37 of 65) patients became ready for 
decannulation 24-72 hrs after PES. Clinical dysphagia scores (DSRS, FOIS) did not differ 
between the treatment groups (Table 2),  
During the randomised part of the study, mean PES stimulation intensity and threshold were 
33.6 mA (SD 8.3) and 15.2 mA (SD 9.3) respectively (Table S5 in the Supplementary 
Appendix).  
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The average time needed for the initial catheter-insertion was 8.7 min (median 6.4, range 2-
30 min), and 70% (44/63) of users judged this procedure to be very easy (score of 6 or 7 on 
the rating score; Figure S4 in the Supplementary Appendix). The stimulation catheter could 
not be inserted in two patients (one prior to randomisation, one prior to the second treatment 
phase).  
While at baseline and directly after study intervention the majority of patients needed to be 
treated on the intensive or intermediate care unit, during follow-up, level of care decreased in 
most of the patients, without any difference between PES- and sham-group (Table 2).  
During the follow-up period, only 20 SLT reports from 9 patients and 2 centres were 
obtained. These reports documented a gradual improvement over time in 5 patients, while in 
4 patients no oral intake was possible. Since these data did not add information to the 
documented dysphagia scores they have not been analysed or presented in detail.  
Seven patients in the PES-group, three patients in the sham-group and one patient prior to 
randomisation died during the study (Table 3). Seven of these occurred >30 days after 
randomisation. None of the deaths having been judged to be PES-treatment or 
investigational device- (base station and catheter) related by the IDSMB. The number of 
patients with at least one serious adverse event (SAE) did not differ between the treatment 
groups (PES=10 (29%) vs. sham=8 (23%), OR 1.3 (0.44-3.83) p=0.7851). No SAEs occurred 
during the second treatment phase of 15 patients who had also received PES during the first 
part of the trial (retreat patients); no serious adverse PES-treatment or investigational device-
related events (SADEs) were observed in the entire study (Table 3). A total of 12 non-serious 
device-related adverse events (ADEs) were observed in eight different patients (Table 3). 
Most notably, in three patients, technical problems with the stimulation device occurred that 
were later resolved. Additionally, in one patient the stimulation catheter could not be placed 
and another one did not tolerate 10 minutes of PES. Finally, one patient experienced 
discomfort during stimulation and removed his stimulation catheter prematurely (for further 
details with regards to SAEs, device-related AEs and AEs please refer to tables S6, S7a, 
S7b and S8 respectively in the Supplementary Appendix). 
Post-hoc, treatment responders (patients deemed ready for decannulation) and non-
responders (patients deemed not ready for decannulation) were compared for different 
outcomes. As shown in Table S9 (Supplementary Appendix), there was a significant 
difference in dysphagia scores between these groups favouring treatment-responders both at 
discharge and 90-day-follow-up. Similarly, treatment responders were discharged 
significantly earlier than treatment non-responders (median LOS after PES was 14 days 
[95% CI 12-15] in responders vs. 36 days [95% CI 16-102] in non-responders, p=0.0006) 
(Figure S5). Finally, when analysing stimulation intensities, patients who responded to PES 
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had lower PES-threshold levels (12.1 vs. 18.5 mA) and a trend to both lower PES-tolerance 
levels (37.0 vs. 42.3 mA) as well as to lower PES-stimulation-intensities (31.2 vs. 36.0 mA) 
than those who did not respond (Table S10 in the Supplementary Appendix). 
To address the issue of blinding at the study sites, a first post-hoc analysis was conducted 
that re-analysed study outcome based on the findings of the independent FEES-Review-
Board. Here, PES was also associated with an increased proportion of patients who were 
ready for decannulation (10 (29%) in the PES group vs. 2 (6%) in the sham group (OR 6.40, 
95%-CI 1.28-31.88; p=0.0234; Table S11 in the Supplementary Appendix), although the 
treatment effect was smaller.  
A second post-hoc analysis was run to evaluate in more detail differences in swallowing 
function between the PES and sham group and to account for differences in patient 
recruitment (both in numbers and clinical characteristics) across study sites. As is shown in 
Figure S6 (Supplementary Appendix), PES was associated with a shift to fewer FEES 
markers of dysphagia (median difference -1.0, 95% CI -2.0, 0.0, p=0180), while the 
proportion of patients with worst scores were similar between groups (10 patients (29%) in 
the PES and 9 (31%) in the sham group). As shown in Table S12 (Supplementary Appendix), 
patients from the study site with highest recruitment differed from other sites with less severe 
stroke (NIHSS 16.3 (SD 3.9) vs. 19.3 (SD 5.1), p=0.0017) and shorter times for onset to 
randomisation (median 23.50 [IQR 18.75-28.25] vs. median 53 [IQR 30-66], p<0.0001) and 
time on ventilator (mean 10.9 (SD 4.7) vs. mean 33.2 (SD 23.4)), p<0.0001). A multiple 
variable model predicting response, and comprising PES, age, onset-to-randomisation 
(OTR), duration of ventilation, NIHSS, and recruitment site (Münster) found that only PES 
and OTR were significantly related to outcome (PES, p=0.0066; OTR, p=0.0361 (Table S13 
in the Supplementary Appendix). 
 
Meta-analysis 
An electronic search for similar trials was performed in PubMed, with the terms “stroke” and 
“dysphagia” in combination with “treatment”, “stimulation”, “therapy”, “rehabilitation”, 
“tracheotomy”, “tracheostomy” or “decannulation” from inception to May 16th 2018. Only trials 
that used PES in tracheotomised stroke patients were selected. A post-hoc summary meta-
analysis of results from the randomised part of PHAST-TRAC and the only other related trial 
conducted by the leading study site in the same population and using the same outcome 
measure24 showed that treatment effects were similar between these two trials and that PES 
was associated with a >10 fold chance of decannulation as compared to sham (Figure S7 in 
the Supplementary Appendix). 
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DISCUSSION 
In this multicentre randomised sham-controlled trial of severely dysphagic tracheotomised 
stroke patients, PES allowed investigators to rate 49% (17/35) patients as ready for 
decannulation in comparison with 9% (3/34) in the control group. Response to treatment 
appeared to be related to a shorter time from stroke onset to randomisation, and shorter 
period on mechanical ventilation. Following both the randomised and open-label parts, more 
than 55% (37/65) of patients who received PES were ready for decannulation and patients 
responding to PES were discharged from hospital significantly earlier than non-responders.  
The effect size of PES in this study was in keeping with that of an earlier single-centre pilot 
trial,24 as summarised in the meta-analysis. Similarly, the low rate of spontaneous recovery in 
the control group is compatible with the “Decannulation and Functional Outcome After 
Tracheostomy in Patients with Severe Stroke” (DECAST) cohort study, where only 26% 
(14/53) of tracheotomised stroke patients could be decannulated within 3 months of stroke.17 
The relationship between treatment efficacy and short times to treatment is presumably 
related to the development of critical illness dysphagia due to critical illness polyneuropathy 
and myopathy in patients with prolonged ICU treatment and mechanical ventilation.33,34 Apart 
from stroke-related impairment of the central swallowing network, polyneuropathy and 
myopathy will damage swallowing related cranial nerves and muscles, respectively. Further, 
PES is critically dependent on intact laryngeal and pharyngeal sensory afferent pathways, so 
that severe polyneuropathy may interfere with its known effect on brain plasticity. Although 
the present study did not include neurophysiological evaluations, the higher sensory 
thresholds observed in patients who were not deemed ready for decannulation as compared 
to successfully treated ones, supports the notion of impaired sensory feedback as an 
important reason for treatment failure. 
Another key finding of this trial was that a second cycle of PES proved to be effective in 
approximately 25% (4/15) of patients still requiring a tracheal cannula after having received 
PES. This result is in line with a recent open-label cohort study35 and suggests that patients 
who do not respond to one cycle (three days) of treatment should be treated with a second.  
Apart from confirming the present results, future trials should therefore particularly focus on 
the substantially more difficult to treat group of tracheotomised stroke patients with longer 
times from stroke-onset (>>28 days) and longer times of preceding mechanical ventilation 
(>>15 days). These trials should allow for the possibility of repetitive PES and, ideally, 
determine potential biomarkers of treatment success.  
The positive results of the present study are clearly different from that of the STEPS trial, 
where PES, applied according to the same treatment paradigm, did not improve swallowing 
safety (primary endpoint) or clinical dysphagia scores (secondary endpoints) in a cohort of 
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126 non-ventilated stroke patients.21 Although, based on the data available, no firm 
conclusions with regards to the reasons for these discrepant findings can be drawn, some 
key differences between both trials might help in providing some tentative explanations. First, 
STEPS recruited less severely affected stroke patients (mean NIH of below 10, as compared 
to 17.5 in PHAST-TRAC) and many were on a partial oral diet at study inclusion. Second, in 
STEPS the median OTR time was 11 days as compared to 28 days in PHAST-TRAC, which 
suggests that spontaneous recovery of PSD might have been more prevalent in STEPS than 
in PHAST-TRAC. Last, stimulation intensities were different with a mean of 14.5 mA in 
STEPS compared to 33.6 mA in PHAST-TRAC, which suggests that PES may have been 
given at a more effective dose in PHAST-TRAC. 
The strength of this phase III trial is its multicentre sham-controlled design in a well-defined 
group of stroke patients and consistent results across the blind and open-label parts of the 
study. However, some limitations are apparent. First, the trial, whilst being the largest study 
of PES in this cohort of patients, was still small, reflecting the adaptive design which led to a 
reduction in sample size. Nevertheless, the findings have robust confidence intervals and are 
consistent both internally and externally. Second, PES was delivered in a single-blind fashion 
with the person providing PES being unblinded. Since both treatment and endpoint 
assessments were done locally at the sites, this might have introduced a bias, although 
endpoint assessors were blinded for patients’ randomisation. To address this concern 
prospectively, an independent review board blinded to recruitment site and treatment 
assignment, re-evaluated videos from the primary outcome FEES examination, and their 
results are compatible with the findings of investigators. Third, the primary outcome was 
assessed a few days after the end of treatment after which open-label treatment was offered 
to all patients who did not reach the primary outcome, irrespective of their treatment group. 
As a result, the effect of randomised treatment on long term outcomes was not possible. 
Nevertheless, 20 patients benefitted from this additional opportunity for active treatment. 
Fourth, the mean age of the sham group was numerically higher than that of the treatment 
group which might have had a negative impact of the recovery rate in the first group. 
However, since the subgroup analysis did not show an interaction of age and PES, this 
baseline difference may not have impacted on the result. Last, the majority of patients were 
recruited from one site and their experience and treatment delivery approach may underpin 
the primary outcome result. Therefore, a replication of findings, preferentially in a larger trial, 
would seem desirable. However, early recruitment after stroke rather than the recruiting site 
appeared to predict response in multiple variable modelling. 
In conclusion, in severely dysphagic, tracheotomised stroke patients, PES was safe and 
superior to sham in improving airway protection and swallowing function and led to higher 
rates of decannulation.  
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Future trials should confirm these results and explore the effect of PES in other cohorts of 
tracheotomised patients. 
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Figure 1. CONSORT flow diagram  
 
NG=Nasogastric, SAE = Serious Adverse Event, DSRS = Dysphagia Severity Rating Scale, 
FOIS = Functional Oral Intake Scale, RASS = Richmond Agitation and Sedation Scale, 
NIHSS = National Institute of Health Stroke Scale; mRS = modified Rankin Scale   
81 PATIENTS Enrolled
Excluded: 
-10 Screen Failures
-1 Death
Excluded: 1  SAE (No NG 
catheter positioned)
CONTROL/SHAM: 
34 PATIENTS
ACTIVE: 
35 PATIENTS
3 READY FOR 
DECANNULATION
31 NOT READY FOR 
DECANNULATION
17 NOT READY FOR 
DECANNULATION
17 READY FOR 
DECANNULATION
Excluded:-1  SAE
(Surgical Intervention and 
patient death)*
Excluded: -1 SAE 
(Impossible to position NG 
catheter) 
Excluded: -1  SAE (Ulcer 
preventing protocol required 
replacement of NG catheter)
30 PATIENTS :
Received FIRST PES
16 PATIENTS: 
Received SECOND PES
PART 1:
Primary Endpoint Assessment
PART  2: 
Secondary Endpoint Assessments
16 READY FOR 
DECANNULATION
14 NOT READY FOR 
DECANNULATION
4 READY FOR 
DECANNULATION
11 NOT READY FOR 
DECANNULATION
Excluded: 
-1 Consent Withdrawal 
PART  2: 
Open-Label Treatments
48 hrs: Re-Assessment of Patient’s Intubation Status (n= 68)
Excluded: 
-9 Deaths
-4 Lost To Follow Up
69 PATIENTS
Randomised
70 PATIENTS
Eligible
Day 30 or Hospital Discharge (whichever is first): Assessment of SAEs, Re-cannulations, Swallowing (DSRS, FOIS), Stroke Severity (NIHSS, mRS), RASS (n=65)
Day 90: Assessment of SAEs, Swallowing (DSRS, FOIS), Stroke Severity (NIHSS, mRS), RASS (n=52)
*Adjudicated as treatment failure (primary end-point)
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Table 1. Baseline characteristics of 69 randomised patients. 
 All PES Sham 
Patients 69 35 34 
Age (years) 64.2 (11.9) 61.7 (13.0) 66.8 (10.3) 
Sex, female (%) 25 (36) 11 (31) 14 (41) 
mRS premorbid >0 (%) 3 (4.6) 1 (3.0) 2 (6.2) 
mRS>4 (%) 67 (99) 34 (100) 33 (97) 
Medical history (%)    
   Hypertension 49 (71) 23 (66) 26 (77) 
   Hyperlipidaemia 4 (6) 1 (3) 3 (9) 
   Diabetes 8 (12) 3 (9) 5 (15) 
   Atrial fibrillation 5 (7) 3(9) 2 (6) 
   Previous stroke/TIA 10 (15) 7 (20%) 3 (9) 
   Smoking 8 (12) 5 (14) 3 (9) 
OTR (days) 28.0 [19, 41] (11-
120) 
28.0 [20, 49] (11-
120) 
28.0 [18, 40] (11-95) 
Ventilation (days, range) 15.0 [9, 22] (3-131) 15.0 [9, 24] (5, 
131) 
13.5 [9, 22] (3, 60) 
Feeding status, PEG (%) 9 (21) 5 (23) 4 (18) 
NIHSS (/24) 17.5 (4.6) 17.6 (5.0) 17.5 (4.3) 
Ischaemic Stroke (%) 49 (71) 27 (77) 22 (65) 
Haemorrhagic Stroke (%) 20 (29) 8 (23) 12 (35) 
Lesion side, right (%) 33 (48) 17 (49) 16 (47) 
DSRS (/12) 12 (0) 12 (0) 12 (0) 
FOIS (/7) 1 (0) 1 (0) 1 (0) 
 
Number of patients enrolled (randomised) per site: Münster 40 (40), Hamburg 14 (8), Aachen 
8 (6), Monza 6 (5), Munich 4 (4), Berlin Median 3 (2), Berlin Vivantes 2 (2), Linz 2 (2), 
Giessen 2 (0). 
DSRS: dysphagia severity rating scale; FOIS: functional oral intake scale; ICH: intracerebral 
haemorrhage; IS: ischemic stroke; NIHSS: National Institute of Health Stroke Scale; mRS: 
modified Rankin Scale; OTR: Onset-to-randomisation time (days); PES: pharyngeal electrical 
stimulation. 
Data are number (%), median [interquartile range] (with range), or mean (standard 
deviation). There were no significant differences between the treatment groups. 
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Table 2. Primary and related outcomes in the randomised and open label parts of the trial 
with sensitivity analyses. 
 N PES Sham OR/MD 
(95% CI) 
p 
Primary Outcome 
Randomised Part 1 of the study      
Patients 69 35 34   
”Ready for decannulation” after 
PES/Sham) (%) 
(Primary outcome) 
 17 (49) 3 (9) 7.00 (2.41-
19.88) 
0.00082 
Removal of the tracheal 
tube (%)* 
 14 (82) 1 (33) 9.33 (0.62-
139.57) 
0.1404 
Deflation of the tube-
cuff (%)* 
 3 (18) 1 (33) 0.43 (0.03-
6.41) 
0.5088 
Secondary Outcomes      
Open Label (Part 2) of the study      
Patients 45 15 30   
”Ready for decannulation” after 
open label treatment)** (%) 
20 (44) 4 (27) 16 (53) 0.32 (0.08-
1.23) 
0.1185 
Removal of the tracheal 
tube (%)* 
17 (38) 3 (20) 14 (47) 0.29 (0.07-
1.22) 
0.1097 
Deflation of the tube-
cuff (%)* 
3 (7) 1 (7) 2 (7) 1.00 (0.08-
12.00) 
1.0000 
Re-cannulation within 48 hrs (%)  0 (0) 0 (0) - - 
Re-cannulation within 30 days or 
hospital discharge (whichever is first) 
(%) 
 0 (0) 0 (0) - - 
DSRS      
Day 2 60 30, 10.6 
(2.4) 
30, 10.4 
(2.7) 
0.27 (-
1.05, 1.59) 
0.6873 
Day 30 or Hospital Discharge 
(whichever is first) 
50 25, 8.0 
(4.6) 
25, 8.9 
(3.3) 
-0.88 (-
3.17, 1.41) 
0.4437 
Day 90 53 27, 4.6 
(5.3) 
26, 5.7 
(5.1) 
-1.10 (-
3.97, 1.77) 
0.4449 
FOIS      
Day 2 61 31, 1.7 
(1.2) 
30, 1.9 
(1.4) 
-0.191 (-
0.878, 
0.495) 
0.5789 
Day 30 or Hospital Discharge 
(whichever is first) 
50 25, 3.0 
(2.4) 
25, 2.5 
(1.7) 
0.560 (-
0.61, 1.73) 
0.3407 
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Day 90 53 27, 4.6 
(2.6) 
26, 3.9 
(2.5) 
0.745 (-
0.660, 
2.150) 
0.2922 
NIHSS      
Baseline 68 34, 17.6 
(5.0) 
34, 17.5 
(4.3) 
0.118 (-
2.129, 
2.364) 
0.9170 
Day 2 47 24, 15.6 
(4.5) 
23, 15.7 
(6.4) 
-0.027 (-
3.287, 
3.233) 
0.9867 
Day 30 or Hospital Discharge 
(whichever is first) 
48 24, 14.0 
(5.0) 
24, 13.8 
(5.9) 
0.292 (-
2.865, 
3.448) 
0.8533 
Day 90 16 8, 10.1 
(9.2) 
8, 16.9 
(8.6) 
-6.750 (-
16.281, 
2.781) 
0.1510 
mRS      
Baseline 68 34, 5.0 
(0.0) 
34, 5.0 
(0.2) 
0.029 (-
0.029, 
0.088) 
0.3210 
Day 2 61 31, 4.6 
(1.3) 
30, 4.6 
(1.3) 
0.078 (-
0.570, 
0.727) 
0.8094 
Day 30 or Hospital Discharge 
(whichever is first) 
54 28, 4.8 
(0.5) 
26, 4.7 
(0.5) 
0.091 (-
0.163, 
0.345) 
0.4769 
Day 90 51 26, 4.1 
(0.8) 
25, 4.3 
(1.0) 
-0.203 (-
0.730, 
0.324) 
0.4421 
Level of care      
Baseline 
Patients 
 
65 
 
32 
 
33 
  
Intensive Care Unit  8 (25) 7 (21) 1.24 (0.39-
3.93) 
0.7746 
Intermediate Care Unit  21 (66) 23 (70) 0.83 (0.29-
2.35) 
0.7944 
Normal ward  3 (10) 3 (10) 1.03 (0.19-
5.55) 
1.0000 
Day 2 
Patients 
 
50 
 
25 
 
25 
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Intensive Care Unit  3 (12) 1 (4) 3.27 (0.32-
33.84) 
0.6092 
Intermediate Care Unit  15 (60) 16 (64) 0.84 (0.27-
2.65) 
1.0000 
Normal ward  7 (28) 8 (32) 0.83 (0.25-
2.78) 
1.0000 
Day 10 
Patients 
 
24 
 
13 
 
11 
  
Intensive Care Unit  2 (15) 1 (9) 1.82 (0.14-
23.25) 
1.0000 
Intermediate Care Unit  4 (31) 5 (46) 0.53 (0.10-
2.84) 
0.6752 
Normal ward  7 (54) 5 (46) 1.40 (0.28-
7.02) 
1.0000 
Day 30 
Patients 
 
14 
 
7 
 
7 
  
Intensive Care Unit  0 (0) 0 (0) - - 
Intermediate Care Unit  2 (29) 1 (14) 2.40 (0.16-
34.93) 
1.0000 
Normal ward  5 (71) 6 (86) 0.42 (0.03-
6.06) 
1.0000 
 
DSRS: dysphagia severity rating scale; FOIS: functional oral intake scale; NIHSS: National 
Institute of Health Stroke Scale; mRS: modified Rankin Scale; PES: pharyngeal electrical 
stimulation. 
Data are number odds ratio (OR) (95% confidence interval); comparison using triangular test 
for primary outcome as specified in trial protocol, and Fisher’s exact test otherwise. Data for 
DSRS. FOIS, NIHSS, mRS are N, Mean (SD); comparison using two-sample t-test. Day 2 is 
48 hrs after final PES treatment. 
* statistical comparison within the subgroup of patients reaching the primary endpoint. 
** This is data related only to the open label part of the study where all non-responders were 
given PES. 
† One patient in the PES group had a non-treatment-related adverse event occurring prior to 
third day of PES which required transfer to another hospital for surgery; as a result, FEES 
assessment was not possible. Conservatively, he was assigned to no decannulation. 
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Table 3. Adverse events (AEs) and serious adverse events (SAEs) 
 PES Sham Non-randomised** 
SAEs: 
Prior randomisation* 1 (1) 1 (1) 3 (2) 
0-1 month after 
randomisation 
3 (3) 4 (4)  
1-3 months after 
randomisation 
8 (7)  4 (1)  
TOTAL study 12 (10) 9 (8) 3 (2) 
Most commonly 
observed SAEs (3 
events) 
   
Pneumonia 2 (2) 1 (1)  
Cardiac Arrest 2 (2) 1 (1)  
Sepsis 3 (3) 4 (4)  
Hydrocephalus 2 (2) 0 (0) 1 (1) 
AE (non-serious) 55 (21) 50 (21) 0 (0) 
Most commonly 
observed AEs (3 
events) 
   
Diarrhoea 2 (2) 4 (4)  
Vomiting 6 (4) 6 (2)  
Pneumonia 3 (3) 6 (5)  
Urinary Tract 
Infection 
8 (7) 3 (3)  
Infection (Other) 6 (6) 4 (3)  
Musculoskeletal 
Pain 
3 (2) 0 (0)  
Hypoxia 2 (2) 1 (1)  
Thrombophlebitis 2 (2) 1 (1)  
Adverse Device-related Events 
(ADEs) 
8 (5) 4 (3) 0 (0) 
Most commonly 
observed ADEs (3 
events) 
   
Medical Device 
Complication 
6 (5) 3 (2) 0 (0) 
Serious ADEs (SADEs) 0 (0) 0 (0) 0 (0) 
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Figures are shown as number of events (number of patients). None of the patient deaths or 
SAEs reported were judged to be intervention- (PES-treatment) or investigational device 
(Phagenyx® base station and catheter)-related by the Independent Data and Safety 
Monitoring Board. 
*Prior randomisation is defined as period from date of informed consent to date of 
randomisation. 
**Non-randomised is defined as patients who were never ultimately randomised. 
ADEs, also referred to as device deficiencies, are defined as an inadequacy of the medical 
device with respect to its identity, quality, durability, reliability, safety or performance. This 
includes malfunctions, use errors, and inadequate labelling. 
See Supplementary Appendix Tables S5 (SAEs), S6a and S6b (ADEs) and S7 (AEs) for 
further details.  
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Figure 2. Forest plot of treatment by subgroup interactions.  
 Data for variables are presented dichotomised using the median of each variable except for 
Average Stimulation Intensity where the mean was used. Only OTR and Ventilation time 
were significantly related to treatment success. Age: patient age in years, OTR: Onset-to-
randomisation time (days), NIHSS: National Institute of Health Stroke Scale. 
 
 
 
 
